Study: NCT02355561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 (Treatment A)
Description: Participants will receive a single oral 25 mg formulation 1 of JNJ-54861911 tablet as Treatment A under fasted conditions in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 (Treatment A)
Description: Participants will receive a single oral 25 mg formulation 1 of JNJ-54861911 tablet as Treatment A under fasted conditions in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 (Treatment A)
Description: Participants will receive a single oral 25 mg formulation 1 of JNJ-54861911 tablet as Treatment A under fasted conditions in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 (Treatment A)
Description: Participants will receive a single oral 25 mg formulation 1 of JNJ-54861911 tablet as Treatment A under fasted conditions in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 (Treatment A)
Description: Participants will receive a single oral 25 mg formulation 1 of JNJ-54861911 tablet as Treatment A under fasted conditions in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 (Treatment A)
Description: Participants will receive a single oral 25 mg formulation 1 of JNJ-54861911 tablet as Treatment A under fasted conditions in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 (Treatment B)
Description: Participants will receive a single oral 25 mg formulation 2 of JNJ-54861911 tablet as Treatment B under fasted conditions in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 (Treatment B)
Description: Participants will receive a single oral 25 mg formulation 2 of JNJ-54861911 tablet as Treatment B under fasted conditions in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 (Treatment B)
Description: Participants will receive a single oral 25 mg formulation 2 of JNJ-54861911 tablet as Treatment B under fasted conditions in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 (Treatment B)
Description: Participants will receive a single oral 25 mg formulation 2 of JNJ-54861911 tablet as Treatment B under fasted conditions in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 (Treatment B)
Description: Participants will receive a single oral 25 mg formulation 2 of JNJ-54861911 tablet as Treatment B under fasted conditions in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 (Treatment B)
Description: Participants will receive a single oral 25 mg formulation 2 of JNJ-54861911 tablet as Treatment B under fasted conditions in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 (Treatment C)
Description: Participants will receive a single oral 25 mg formulation 2 of JNJ-54861911 tablet as Treatment C under fed conditions in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 (Treatment C)
Description: Participants will receive a single oral 25 mg formulation 2 of JNJ-54861911 tablet as Treatment C under fed conditions in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 (Treatment C)
Description: Participants will receive a single oral 25 mg formulation 2 of JNJ-54861911 tablet as Treatment C under fed conditions in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 (Treatment C)
Description: Participants will receive a single oral 25 mg formulation 2 of JNJ-54861911 tablet as Treatment C under fed conditions in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 (Treatment C)
Description: Participants will receive a single oral 25 mg formulation 2 of JNJ-54861911 tablet as Treatment C under fed conditions in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 (Treatment C)
Description: Participants will receive a single oral 25 mg formulation 2 of JNJ-54861911 tablet as Treatment C under fed conditions in one of the treatment periods.